drugset / Trial / NCT00410410

A Study of Abatacept in Patients With Active Ulcerative Colitis

NCT00410410

Phase 3 Completed 591 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active ulcerative colitis in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied

Timeline

Start
2006-12
Primary completion
2009-06
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 3 mg/kg Intravenous
Subject Abatacept Other / unclassified 10 mg/kg Intravenous

Indications